SCHEMBL5545196

SCHEMBL5545196

FC(F)(F)Oc1cc(O[CH]c2ccccc2)cc(OC(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.38
PIM2 Q9P1W9 2/20 0.38
METAP2 P50579 1/20 0.37
KIF11 P52732 3/20 0.37
GPR3 P46089 2/20 0.37
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
MITF O75030 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
GRIN2B Q13224 2/20 0.33
SCN5A Q14524 1/20 0.33
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
BACE1 P56817 1/20 0.32
SLC40A1 Q9NP59 1/20 0.32
ACP1 P24666 1/20 0.32
GRIN1 Q05586 1/20 0.32
KAT6A Q92794 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543869 0.78 IDO1 (0.44) KIF11MEN1NPC1RAB9AKMT2A
SCHEMBL5542866 0.76 MRGPRX4 (0.42) PIM1PIM2KIF11GPR3SCN5A
SCHEMBL5540271 0.75 ALDH1A1 (0.50) MEN1KMT2A
SCHEMBL5540895 0.73 EGFR (0.39) MEN1KMT2A
SCHEMBL536918 0.73 TSHR (0.43)
SCHEMBL5540388 0.71 NPSR1 (0.41) MEN1KMT2AACHE
SCHEMBL6001487 0.71 PIM1 (0.44) PIM1PIM2KIF11GPR3MEN1
SCHEMBL20283189 0.70 NFE2L2 (0.50) PIM1PIM2KIF11
SCHEMBL168125 0.70 KIF11 (0.47) KIF11GPR3MEN1RAB9AKMT2A
SCHEMBL27862141 0.70 KIF11 (0.47) KIF11GPR3MEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PIM1 3129/4885PIM2 2557/4885METAP2 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.